SCHOLAR ROCK HOLDING CORPORATION (SRRK) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $122.00K; Additional Paid in CapitalUSD $1.77B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $1.14M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $119.00K; Additional Paid in CapitalUSD $1.68B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $690.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $108.00K; Additional Paid in CapitalUSD $1.55B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $94.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $99.00K; Additional Paid in CapitalUSD $1.45B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $117.00K.
SCHOLAR ROCK HOLDING CORPORATION Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $122.00K | $1.77B | $1.14M | $-1.52B | $253.78M | 3 month · $19.66M |
| 2026-03-31 | (m) | $119.00K | $1.68B | $690.00K | $-1.41B | $276.01M | 3 month · $18.25M |
| 2025-12-31 | $0.00 | $108.00K | $1.55B | $94.00K | $-1.30B | $245.49M | 12 month · $75.60M |
| 2025-09-30 | (m) | $99.00K | $1.45B | $117.00K | $-1.21B | $245.00M | 3 month · $18.33M |
| 2025-06-30 | (m) | $96.00K | $1.34B | $58.00K | $-1.11B | $233.29M | 3 month · $24.43M |
| 2025-03-31 | (m) | $95.00K | $1.31B | $129.00K | $-997.44M | $312.33M | 3 month · $13.41M |
| 2024-12-31 | (m) | $94.00K | $1.29B | $160.00K | $-922.72M | $368.63M | 12 month · $36.63M |
| 2024-09-30 | (m) | $80.00K | $935.25M | $128.00K | $-856.26M | $79.20M | 3 month · $9.65M |
| 2024-06-30 | (m) | $80.00K | $925.38M | $-54.00K | $-791.78M | $133.62M | 3 month · $9.31M |
| 2024-03-31 | (m) | $80.00K | $916.02M | $-50.00K | $-733.27M | $182.77M | 3 month · $8.16M |
| 2023-12-31 | (m) | $76.00K | $901.47M | $92.00K | $-676.42M | $225.22M | 12 month · $27.14M |
| 2023-09-30 | (m) | $56.00K | $797.93M | $-23.00K | $-630.29M | $167.66M | 3 month · $7.20M |
| 2023-06-30 | (m) | $55.00K | $790.45M | $-63.00K | $-587.94M | $202.50M | 3 month · $6.82M |
| 2023-03-31 | (m) | $52.00K | $778.94M | $-329.00K | $-550.01M | $228.65M | 3 month · $6.17M |
| 2022-12-31 | (m) | $52.00K | $771.70M | $-884.00K | $-510.63M | $260.24M | 12 month · $27.70M |
| 2022-09-30 | (m) | $52.00K | $765.53M | $-936.00K | $-471.38M | $293.26M | 3 month · $7.92M |
| 2022-06-30 | (m) | $52.00K | $757.61M | $-79.00K | $-428.08M | $329.51M | 3 month · $6.79M |
| 2022-03-31 | (m) | $35.00K | $555.51M | $-152.00K | $-384.08M | $171.32M | 3 month · $6.83M |
| 2021-12-31 | (m) | $35.00K | $548.20M | $-35.00K | $-376.13M | $172.07M | 12 month · $23.15M |
| 2021-09-30 | (m) | $35.00K | $527.44M | (m) | $-340.22M | $187.26M | 3 month · $6.15M |
| 2021-06-30 | (m) | $34.00K | $519.32M | $9.00K | $-302.71M | $216.66M | 3 month · $6.23M |
| 2021-03-31 | (m) | $34.00K | $512.49M | $23.00K | $-272.00M | $240.54M | 3 month · $4.67M |
| 2020-12-31 | (m) | $34.00K | $505.07M | $-2.00K | $-244.33M | $260.77M | 12 month · $11.18M |
| 2020-09-30 | (m) | $30.00K | $280.70M | $3.00K | $-217.76M | $62.98M | 3 month · $4.04M |
| 2020-06-30 | (m) | $30.00K | $276.29M | $49.00K | $-194.20M | $82.17M | 3 month · $2.40M |
| 2020-03-31 | (m) | $30.00K | $273.30M | $234.00K | $-174.92M | $98.65M | 3 month · $2.21M |
| 2019-12-31 | (m) | $30.00K | $270.68M | $37.00K | $-157.85M | $112.90M | 12 month · $7.97M |
| 2019-09-30 | (m) | $30.00K | $268.01M | $26.00K | $-146.28M | $121.79M | 3 month · $2.69M |
| 2019-06-30 | (m) | $29.00K | $259.00M | $58.00K | $-130.13M | $128.96M | 3 month · $1.81M |
| 2019-03-31 | (m) | $26.00K | $215.08M | $16.00K | $-117.60M | $97.52M | 3 month · $1.62M |
| 2018-12-31 | (m) | $26.00K | $213.45M | $-8.00K | $-106.85M | $106.62M | 12 month · $5.21M |
| 2018-09-30 | (m) | $25.00K | $194.20M | (m) | $-91.89M | $102.34M | 3 month · $1.49M |
| 2018-06-30 | (m) | $25.00K | $192.71M | (m) | $-81.12M | $111.61M | 3 month · $1.09M |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | $-61.93M | 3 month · $482.00K |
| 2017-12-31 | (m) | $4.00K | $4.00M | $-2.00K | $-57.52M | $-53.52M | 12 month · $1.48M |
| 2016-12-31 | (m) | (m) | (m) | (m) | (m) | $-30.03M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |